<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532023</url>
  </required_header>
  <id_info>
    <org_study_id>28825</org_study_id>
    <nct_id>NCT02532023</nct_id>
  </id_info>
  <brief_title>The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients</brief_title>
  <official_title>The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Gene Expression and Serum Levels of Some Inflammatory and Endothelial Factors in Migraine Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the effects of omega 3 fatty acid, curcumin and their
      combination or placebo for 2 months on the gene expression of COX-2, iNOS, TNF-α, IL-1β,
      IL-6, VCAM-1 and ICAM-1 in the peripheral blood mononuclear cell (PBMC) and serum levels of
      COX-2, iNOS, TNF-α, IL-1β, IL-6, VCAM-1, ICAM-1 and hsCRP of migraine patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to determine the effects of omega 3 fatty acid, curcumin and their
      combination or placebo for 2 months on the gene expression of cyclooxygenase-2 (COX-2),
      inducible nitric oxide synthase (iNOS), Tumor necrosis factor-α (TNF-α), interleukin-1β
      (IL-1β), interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1) and intercellular
      adhesion molecule-1 (ICAM-1) in the peripheral blood mononuclear cell (PBMC) and serum levels
      of COX-2, iNOS, TNF-α, IL-1β, IL-6, VCAM-1, ICAM-1 and high-sensitivity C-reactive protein
      (hsCRP) of migraine patients.

      In this randomized, double-blind clinical trial, placebo-controlled study, 80 women and men
      with migraine are enrolled from the Iranian Center of Neurological Research. At the start of
      study, all participants will sign informed consent and complete a general information form.
      24-hour food recall for 3 days will be taken from the patients at the beginning and the end
      of the study. Selected samples by using stratified randomization method based on sex, gender
      and body mass index (BMI) are classified into 4 groups: 1) receiving omega 3 fatty acid
      supplement and curcumin supplement 2) receiving omega 3 fatty acid supplement and curcumin
      placebo 3) receiving curcumin supplement and omega 3 fatty acid placebo 4) receiving omega 3
      fatty acid placebo and curcumin placebo.

      The omega 3 fatty acid supplement group will receive 1200 mg Eicosapentaenoic acid (EPA) and
      600 mg Docosahexaenoic acid (DHA) totally 1800 mg daily for 2 months. The curcumin supplement
      group will receive 1000 mg curcumin daily for 2 months. The omega 3 fatty acid placebo group
      will also receive placebo containing 1800 mg edible paraffin oil and curcumin placebo group
      will receive 1000 mg starch powder both similar in terms of color, shape and size.
      participants are advised to maintain their diet, level of physical activity and medication
      dose during the study. Blood samples will be collected after anthropometric parameter
      measuring then target biochemical parameters, gene expression and serum levels and physical
      activity will be measured before and after the trial.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>headache attack</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum COX-2</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum iNOs</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum VCAM-1</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ICAM-1</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum TNF-α</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum IL-1β</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum IL-6</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum hsCRP</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>headache duration</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>headache severity</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COX-2 gene expression</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iNOs gene expression</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VCAM-1 gene expression</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICAM-1 gene expression</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α gene expression</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1β gene expression</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 gene expression</measure>
    <time_frame>Change frome baseline at 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>omega 3 fatty acid supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with migraine receive 2 capsules 1000 mg omega3, 2 times a day, for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>curcumin supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with migraine receive 2 capsules 1000 mg curcumin, 2 times a day, for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omega 3 fatty acid Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients with migraine receive 2 capsules of omega 3 fatty acid placebo for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>curcumin placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients with migraine receive 2 capsules of curcumin placebo for 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega 3 fatty acid</intervention_name>
    <description>omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months</description>
    <arm_group_label>omega 3 fatty acid supplementation</arm_group_label>
    <other_name>n-3 PUFA</other_name>
    <other_name>n-3 Fatty Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>curcumin</intervention_name>
    <description>curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months</description>
    <arm_group_label>curcumin supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega 3 fatty acid placebo</intervention_name>
    <description>omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months</description>
    <arm_group_label>omega 3 fatty acid Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>curcumin placebo</intervention_name>
    <description>curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months</description>
    <arm_group_label>curcumin placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  migraine patients 20- 50 years old

          -  body mass index more than 18.5

          -  avoidance of dietary supplements, vitamins and herbal products at least 4-6 weeks
             before and throughout the intervention

          -  willingness to participation

        Exclusion Criteria:

          -  sensitivity to omega 3 fatty acid and curcumin

          -  pregnancy and lactation

          -  sever change in regular diet and life style

          -  change in type and dosage of regular medication (s)

          -  inflammatory disease which need take anti inflammatory drugs over than 2 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2015</study_first_posted>
  <last_update_submitted>August 24, 2015</last_update_submitted>
  <last_update_submitted_qc>August 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>omega 3 fatty acid</keyword>
  <keyword>curcumin</keyword>
  <keyword>COX-2</keyword>
  <keyword>iNOs</keyword>
  <keyword>VCAM-1</keyword>
  <keyword>ICAM-1</keyword>
  <keyword>IL-1β</keyword>
  <keyword>IL-6</keyword>
  <keyword>TNF-α</keyword>
  <keyword>hsCRP</keyword>
  <keyword>migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

